Not available
Quote | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
Last: | $0.682 |
---|---|
Change Percent: | -1.4% |
Open: | $0.69 |
Close: | $0.6917 |
High: | $0.7074 |
Low: | $0.65 |
Volume: | 926,120 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
2024-03-28 13:53:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atara Biotherapeutics (NASDAQ: ATRA ) just reported results for the fourth quarter of 2023. Atara Biotherapeutics reported earnings per share of -56 cents. This was below ...
2024-03-28 08:43:25 ET More on Atara Biotherapeutics Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway FDA clears Atara to begin Phase 1 study for lupus nephritis drug Baupost Group steps away from Atara, Veritiv; bulks up on ...
Message Board Posts | Atara Biotherapeutics Inc. (NASDAQ:ATRA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ATRA News Article - Atara Biotherapeutics to Announce First Quarter 2023 Financial Res | whytestocks | investorshangout | 05/01/2023 8:20:47 PM |
whytestocks: $ATRA News Article - Atara Biotherapeutics to Announce Fourth Quarter and Full Year 202 | whytestocks | investorshangout | 02/06/2023 3:35:45 PM |
whytestocks: $ATRA News Article - CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo(TM) (ta | whytestocks | investorshangout | 10/14/2022 12:05:54 PM |
znewcar1: ATRA 25% v6,2M c5.84 f94,4M H5.87 ML2.83 | znewcar1 | investorshangout | 08/12/2022 8:46:00 PM |
znewcar1: ATRA 29% v14,5M c4.69 f93,4M H4.92 ML2.83 gap down | znewcar1 | investorshangout | 08/09/2022 8:10:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans to Initiate an ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 AT...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...